-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical company Inhibikase Therapeutics announced today that its Phase I clinical trial of IkT-148009 to treat Parkinson's has officially begun.
IkT-148009 is an Abelson non-subject tyrosine kinase (c-Abl) inhibitor used to treat Parkinson's.
Abelson non-subject tyrosine kinase (c-Abl) has been linked to nerve spots and neurogenic fiber entanglements in the brains of patients with Alzheimer's disease and other neurodegenerative diseases.
random Phase I study is exploring the safety, toerability, and pharmacodynamics (PK) of IkT-148009 in healthy volunteers ages 45 to 70, with the aim of determining the maximum to-dosage and PK curve of IkT-148009.
in preclinical animal models, the company demonstrated that daily oral treatment with IkT-148009 can prevent and reverse the loss of function in the brain and gastrointestinal tract.
, Chief Executive Officer of Inhibikase Therapeutics, said: "The launch of the Phase I study on the treatment of Parkinson's disease by IkT-148009 represents an important milestone for Inhibik Therapeutics.
Based on preclinical data, we believe that c-Abl plays an important role in the onset of Parkinson's disease, so inhibiting c-Abl represents a promising therapy."
